Resection of thoracic malignancies infiltrating cardiac structures with use of cardiopulmonary bypass

Journal of Cardiothoracic Surgery

Matthias Karck¹  Hendrik Dienemann²  Arjang Ruhparwar¹  Philipp Seppelt¹  Klaus Kallenbach¹  Florian Eichhorn²  Rawa Arif¹ 

[1]Department of Cardiac Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 110, Heidelberg, 69120, Germany

[2]Department of Thoracic Surgery, Thoraxklinik Heidelberg, University Hospital Heidelberg, Heidelberg, Germany

关键词: Thymus;    Metastases;    Mediastinal tumor;    Sarcoma;    Tumor;   

Others  :  1224157
DOI  :  10.1186/s13019-015-0296-8

 received in 2015-02-24, accepted in 2015-06-19,  发布年份 2015

【 摘 要 】

Background

Only few reports exist on malignant thoracic neoplasms that require cardiopulmonary bypass during resection. We aimed to investigate the early and late clinical outcome of these patients.

Methods

Patients with thoracic malignancies that underwent surgery between 2002 and 2014 were analyzed. All patients had cardiopulomonary bypass support during resection. Clinical and perioperative data was retrospectively reviewed for outcome and overall survival.

Results

Fifteen patients (12 female, mean age of 55 ± 15 years, range 24 to 80 years) were identified. Eleven (8 female) were diagnosed with primary thoracic malignomas and four with metastases. Three patients died early postoperatively. Patients diagnosed with sarcoma had a significantly worse outcome than non-sarcoma patients (83.3 ± 15.2 % after 1 year, 31.3 ± 24.5 % after 5 years vs. 83.3 ± 15.2 % after 1 year, 0 ± 0 % after 5 years, p = 0.005).

Conclusions

Malignancies with extension into cardiac structures or infiltration of great vessels can be resected with cardiopulmonary bypass support and tolerable risk. Carefully selected patients can undergo advanced operative procedures with an acceptable 1-year-survival, but only few patients achieved good long-term outcome.

【 授权许可】

   
2015 Arif et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Silverman NA. Primary cardiac tumors. Ann Surg. 1980; 191:127-134.
• [2]Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12485 consecutive autopsies. Arch Pathol Lab Med. 1993; 117:1027-1031.
• [3]Molina JE, Edwards JE, Ward HB. Primary cardiac tumors: experience at the University of Minnesota. Thorac Cardiovasc Surg. 1990; 38 Suppl 2:183-191.
• [4]Burke AP, Cowan D, Virmani R. Primary sarcomas of the heart. Cancer. 1992; 69(2):387-395.
• [5]Putnam JB, Sweeney MS, Colon R, Lanza LA, Frazier OH, Cooley DA. Primary cardiac sarcomas. Ann Thorac Surg. 1991; 51(6):906-910.
• [6]Van der Salm TJ. Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg. 2000; 12(2):89-100.
• [7]Wiebe K, Baraki H, Macchiarini P, Haverich A. Extended pulmonary resections of advanced thoracic malignancies with support of cardiopulmonary bypass. Eur J Cardiothorac Surg. 2006; 29:571-578.
• [8]Vaporciayan AA, Rice D, Correra AM et al.. Resection of advanced thoracic malignancies requiring cardiopulmonary bypass. Eur J Cardiothorac Surg. 2002; 22:47-52.
• [9]Lang G, Taghavi S, Aigner C et al.. Extracorporeal Membrane Oxygenation Support for Resection of Locally Advanced Thoracic Tumors. Ann Thorac Surg. 2011; 92:264-271.
• [10]Martini N, Yellin A, Ginsberg RJ et al.. Management of non–small cell lung cancer with direct mediastinal involvement. Ann ThoracSurg. 1994; 58:1447-1451.
• [11]Pitz CC, Brutel de la Riviere A, van Swieten HA, Westermann CJ, Lammers JW, van den Bosch JM. Results of surgical treatment of T4 non–small cell lung cancer. Eur J CardiothoracSurg. 2003; 24:1013-1018.
• [12]Park BJ, Bacchetta M, Bains MS et al.. Surgical management of thoracic malignancies invading the heart or great vessels. Ann ThoracSurg. 2004; 78:1024-1030.
• [13]Byrne JG, Leacche M, Agnihotri AK et al.. The use of cardiopulmonary bypass during resection of locally advanced thoracic malignancies. A 10-year two-center experience. Chest. 2004; 125:1581-1586.
• [14]Zhang PJ, Brooks JS, Goldblum JR et al.. Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol. 2008; 39(9):1385-1395.
• [15]Simpson L, Kumar SK, Okuno SH et al.. Malignant primary cardiac tumors: review of a single institution experience. Cancer. 2008; 112(11):2440-2446.
• [16]Hill GE, Whitten CW, Landers DF. The influence of cardiopulmonary bypass on cytokines and cell-cell communication. J CardiothoracVascAnesth. 1997; 11:367-375.
• [17]Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993; 55:552-559.
• [18]Edmunds LH. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1998; 66:12-16.
• [19]Halter J, Steinberg J, Fink G et al.. Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass. J Extra Corpor Technol. 2005; 37:272-277.
• [20]Greene FL, Page DL, Fleming ID et al.. American Joint Committee on Cancer (AJCC). AJCC Cancer staging manual. 6th ed. Springer, New York, Berlin, Heidelberg; 2002.
• [21]Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012; 380(9844):848-857.
• [22]Kallenbach K, Cremer J, Haverich A. Partial ex situ surgery of the heart. J Thorac Cardiovasc Surg. 2002; 123(3):577-578.
• [23]Colley DA, Rerdon MJ, Frazier OH, Angelici P. Human cardiac explantation and autotransplantation: application in a patient with a large cardiac pheochromocytoma. Tex Heart inst J. 1985; 12:171-176.
• [24]Li H, Xu D, Chen Z et al.. Prognostic analysis for survival after resections of localized primary cardiac sarcomas: a single-institution experience. Ann Thorac Surg. 2014; 97(4):1379-1385.